AstraZeneca: Pain trials
The registry lists 21 Pain studies with AstraZeneca as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 1 12Phase 2 8Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting AbilityCompletedNCT01928381Phase 2Results posted
- Zomig - Treatment of Acute Migraine Headache in AdolescentsCompletedNCT01211145Phase 4Results posted
- Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)CompletedNCT01019928Phase 2Results posted
- AZD2066 Neuropathic Pain - Mechanical HypersensitivityTerminatedNCT00939094Phase 2Results posted
- Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the KneeTerminatedNCT00878501Phase 2Results posted
- Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic NeuropathyCompletedNCT00857623Phase 2Results posted
- Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386CompletedNCT00672646Phase 2Results posted
- Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940CompletedNCT00659490Phase 2Results posted
- A Study to Assess Therapeutic Equivalence Between Test EMLA Patch With Marketed EMLA Patch in Healthy Subjects.CompletedNCT03313336Phase 1
- Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the KneeTerminatedNCT01072591Phase 1
- Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic PainTerminatedNCT00976534Phase 2
- Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy SubjectsCompletedNCT00972049Phase 1
- Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386CompletedNCT00832169Phase 1
- Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066CompletedNCT00829088Phase 1
- Esophageal Hypersensitivity Study in Healthy VolunteersCompletedNCT00711048Phase 1
- Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)CompletedNCT00692146Phase 1
- Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704CompletedNCT00692042Phase 1
- Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386CompletedNCT00690079Phase 1
- Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940CompletedNCT00689780Phase 1
- Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066CompletedNCT00686504Phase 1
- Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy SubjectsCompletedNCT00684502Phase 1